Guinea-Bissau's Ministry of Health has denied authorizing a controversial study involving newborns and hepatitis B vaccines, asserting that the government "did not authorize" the trial as presented in recent publications. The announcement came from Health Minister Quinhin Nantote on Tuesday, who expressed surprise at media reports suggesting the country had given its approval.

The proposed study, which would withhold hepatitis B vaccines from thousands of newborns in a nation where the disease is prevalent, has drawn significant attention due to its funding sources and the involvement of prominent figures. The trial is reportedly funded by the U.S. government and private partners, and has been championed by Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services and a well-known anti-vaccine activist.

Minister Nantote stated at a press briefing that any research involving human subjects, especially children, must strictly adhere to national legislation, international ethical principles, and competent approval mechanisms. He indicated that the ministry had not agreed to the trial "under the terms presented in the publications currently in circulation," referring to the research as "tests."

The minister's remarks followed an emergency meeting convened in Guinea-Bissau with representatives from the Bandim Health Project, the local ethics committee, the National Institute of Public Health (Inasa), and the Expanded Vaccination Program (PAV). The Bandim Health Project is managed by Danish researchers Peter Aaby and Christine Stabell Benn, whose extensive research has focused on the effects of vaccines.

Reports had indicated that members of a Danish research ethics committee were informed of an updated study design that officials in Guinea-Bissau had approved. This information influenced some committee members' votes to proceed with the trial last week. The study's design has been criticized for not investigating the safety or efficacy of vaccines, but rather tracking "nonspecific" health outcomes such as overall mortality or neurodevelopmental conditions.

This denial by Guinea-Bissau's health ministry raises questions about the communication between the research teams, local authorities, and international ethics committees. The discrepancy highlights the complex ethical considerations and approval processes involved in international health research, particularly when public health interventions are involved.

Further clarification is expected regarding the exact status of the study and the reasons for the apparent miscommunication. The ministry's firm stance underscores the importance of rigorous ethical oversight and national sovereignty in approving research conducted within its borders, especially when it concerns vulnerable populations like newborns.

The situation also brings renewed focus to the broader debate surrounding vaccine research and the influence of public figures on scientific initiatives. The involvement of Robert F. Kennedy Jr. has already placed the trial under intense scrutiny from public health advocates and the scientific community.